Frunevetmab Explained

Type:mab
Mab Type:mab
Source:a
Target:Nerve growth factor (NGF)
Tradename:Solensia
Dailymedid:Frunevetmab
Routes Of Administration:Subcutaneous
Atcvet:yes
Atc Prefix:N02
Atc Suffix:BG90
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Us:Rx-only
Legal Us Comment:[2]
Legal Eu:Rx-only
Legal Eu Comment:[3]
Cas Number:1708936-80-4
Unii:77O28MCS79
Kegg:D10935

Frunevetmab, sold under the brand name Solensia, is a monoclonal antibody used to treat pain associated with osteoarthritis in cats.[4] It is the first monoclonal antibody drug approved by the US Food and Drug Administration for animal use. Frunevetmab is the international nonproprietary name.[5]

Clinical usage

Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor that is involved in the regulation of pain. When frunevetmab binds to nerve growth factor, it prevents the pain signal from reaching the brain.

Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.

The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).

History

In February 2021, frunevetmab was approved for medical use in the European Union.

In January 2022, frunevetmab was approved for medical use in the United States.[6]

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis.[7]

Bibliography

Notes and References

  1. Web site: Health product highlights 2021: Annexes of products approved in 2021 . . 3 August 2022 . 25 March 2024.
  2. Web site: NADA 141-546 Solensia frunevetmab injection Injectable Solution Cats . U.S. Food and Drug Administration (FDA) . https://web.archive.org/web/20220115030222/https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817 . 15 January 2022 . live .
  3. Web site: Solensia EPAR . European Medicines Agency (EMA) . 11 December 2020 . 14 January 2022 . 15 January 2022 . https://web.archive.org/web/20220115040558/https://www.ema.europa.eu/en/medicines/veterinary/EPAR/solensia . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species . U.S. Food and Drug Administration (FDA) . 13 January 2022 . 14 January 2022 . 13 January 2022 . https://web.archive.org/web/20220113154907/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-control-pain-cats-osteoarthritis-first-monoclonal-antibody-drug-use-any . live .
  5. ((World Health Organization)) . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78 . WHO Drug Information . 31 . 3 . 2017 . 10665/330961 . free . World Health Organization .
  6. Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats . Zoetis . 13 January 2022 . 14 January 2022 . 13 January 2022 . https://web.archive.org/web/20220113235612/https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-FDA-Approval-of-Solensia-frunevetmab-injection-to-Control-Osteoarthritis-Pain-in-Cats/default.aspx . live .
  7. Web site: FDA Approves Pain Reliever for Cats Considered Too Risky for Humans . 14 January 2022 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Frunevetmab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.